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The transcription factor FOXP3 has been identified as a tumour suppressor in breast and 
prostate epithelia, but little is known about its specific mechanism of action. We have 
identified a feed-forward regulatory loop in which FOXP3 suppresses the expression of the 
oncogene SATB1. In particular, we demonstrate that SATB1 is not only a direct target of 
FOXP3 repression but that FOXP3 also induces two microRNAs; miR-7 and miR-155, which 
specifically target the 3' UTR of SATB1 to further regulate its expression. We conclude that 
FOXP3-regulated microRNAs form part of the mechanism by which FOXP3 prevents the 
transformation of healthy breast epithelium to a cancerous phenotype. Approaches aimed at 
restoring FOXP3 function and the miRs it regulates could help provide new approaches to 




The X-linked gene FOXP3 is a member of the Forkhead/winged helix family of 
transcription factors which was first identified as essential for the formation and function of T 
regulatory (Treg) cells. Treg are a rare subset of T cells responsible for preventing 
inappropriate immune responses and promoting immune tolerance (Feuerer et al., 2009; 
Fontenot et al., 2003; Josefowicz and Rudensky, 2009; Marson et al., 2007).  Although 
originally thought to be T cell-restricted, FOXP3 expression appears widespread in normal 
epithelia and aberrant in solid tumours, suggesting that FOXP3 can function as a tumour 
suppressor (Chen et al., 2008; Ladoire et al., 2011; Martin et al., 2010). Compelling evidence 
for this comes from the observation that female heterozygous Foxp3 knockout mice have a 
significant age-dependent increase in the incidence of spontaneous cancer, in particular 
mammary cancer. Critically, tumour cells, but not adjacent normal breast tissue from these 
mice showed skewed X-inactivation, resulting in the exclusive loss of the WT Foxp3 allele in 
the cancer (Zuo et al., 2007b). Further evidence for a tumour suppressor role comes from 
prostate-specific ablation of FOXP3 by conditional gene targeting, which leads to prostate 
hyperplasia and precancerous lesions (Wang et al., 2009). FOXP3 also appears to have 
tumour suppressor functions in human epithelial cells as several studies report a high 
frequency of somatic mutations and deletions of FOXP3 in human breast, ovary and prostate 
tumour samples (Zuo et al., 2007a; Zuo et al., 2007b). In addition, the reintroduction of 
FOXP3 into breast or prostate cancer cell lines has growth inhibitory and pro-apoptotic 
effects on these cancer cell lines in vitro and in vivo (Wang et al., 2009; Zhang et al., 2006; 
Zuo et al., 2007a).  
 
FOXP3 is able to function as a transcriptional repressor or activator in both Treg (Marson et 
al., 2007; Sadlon et al., 2010; Zheng et al., 2007) and epithelial cells. For example, FOXP3 
directly represses the ERBB2 and SKP2 oncogenes whilst maintaining p21 tumour suppressor 
expression in breast epithelium (Liu et al., 2009a; Zuo et al., 2007a; Zuo et al., 2007b). In 
prostate cells, FOXP3 has also been shown to directly repress c-myc transcription (Wang et 
al., 2009), an oncogene frequently over-expressed in many types of human cancer (Wolfer et 
al., 2010). More recently, induction of FOXP3 by p53 following DNA damage in breast 
epithelial cells has been reported with increased FOXP3 levels contributing to the growth 
suppressive activity of the p53 pathway (Jung et al., 2010). Together these data suggest that 
FOXP3 is itself regulated by tumour suppressors and it controls key oncogenes and tumour 
suppressors in epithelial cells, although the mechanisms and pathways have yet to be fully 
elucidated. This raises the question as to whether FOXP3 is linked to other genes involved in 
maintaining breast epithelium.  
 
Whilst the targets of FOXP3 in epithelial cells are still largely unknown,  genome-wide 
chromatin immunoprecipitation (ChIP-on-chip) studies in human and mouse Treg cells have 
identified a large number of potential FOXP3 target genes, including a number of loci 
encoding microRNAs, (Marson et al., 2007; Sadlon et al., 2010; Zheng et al., 2007).  The 
extent to which FOXP3 regulates common or unique sets of genes in these two different cell 
types is not currently known, however, the identification of microRNAs as potential targets 
for FOXP3 regulation is of clear interest given their regulatory role in both normal and 
disease tissue. MicroRNAs (miRs) are a class of small non-coding RNAs that modulate gene 
expression by binding to the 3'UTR of target genes, resulting in translational repression and 
increased mRNA degradation (Bartel, 2009; Filipowicz et al., 2008). In breast cancer, 
expression profiling has demonstrated clear differences in the expression of specific miRs 
between normal and primary tumour tissue, with miRs identified that are both up and 
downregulated (Iorio et al., 2005; Volinia et al., 2006). The mechanisms and consequences of 
miR deregulation within a cancer cell are still being determined, although it is likely that 
changes in the levels and activity of transcriptional regulators and miR processing machinery, 
coupled with alterations in miR copy number, will contribute to the overall deregulation of 
miR expression (Selcuklu et al., 2009; Zhang et al., 2006). There is now compelling evidence 
for the participation of miR and transcription factor combinations in feed-back and feed-
forward loops (Bartel, 2009; Brosh et al., 2008; Re et al., 2009; Tsang et al., 2007), and such 
microRNA/transcription factor feed-forward loops have been show to enhance the robustness 
and responsiveness of a regulatory network (Filipowicz et al., 2008).  
 
Special AT-rich Binding Protein 1 (SATB1), an oncogene involved in the promotion 
of breast tumour growth and metastasis (Han et al., 2008; Li et al., 2010a; Li et al., 2010b), is 
expressed in a significant proportion of primary human epithelial breast tumours and  is an 
independent prognostic factor for breast cancer (Han et al., 2008).  SATB1 is expressed in a 
number of metastatic breast cancer cell lines but not in non invasive cell lines (Han et al., 
2008), and furthermore, knockdown of SATB1 in these aggressive breast cancer cells 
significantly inhibited the growth of tumours in both in vitro and in vivo models of 
metastasis, providing strong evidence of its essential role in cancer progression (Han et al., 
2008; Richon, 2008). SATB1 is a DNA binding protein that functions as a global regulator of 
transcription through diverse mechanisms which include the maintenance of specific 
chromatin architecture, such as the creation of chromatin loop domains by selectively 
tethering specific matrix attachment regions (MARs) to the nuclear matrix, and the 
recruitment of chromatin modifying complexes to these anchor points (Cai et al., 2003; 
Galande et al., 2007; Yasui et al., 2002).  
 Here we show that FOXP3 over-expression in the BT549 breast cancer cell line can suppress 
SATB1 mRNA and protein levels. Specifically we show that FOXP3 together with the 
FOXP3-induced miRs hsa-miR-7 (miR-7) and hsa-miR-155 (miR-155) form a feed forward 
regulatory loop to suppress SATB1. We therefore propose that restoration of this regulation 
may provide a new approach in the treatment of breast cancer. 
  
Methods 
Cell lines  
BT549 cells (ATCC, Manassas, Virginia USA) were cultured in RPMI (Thermo Scientific, 
Waltham USA) supplemented with 10% FBS (Sigma-Aldrich, St. Louis, Missouri USA) and 
1% Penicillin/streptomycin solution (Sigma-Aldrich). MDA-MB-231 cells (ATCC) and HEK 
293T cells (ATCC) were cultured in Dulbecco’s modified Eagle Medium (DMEM; Thermo 
Scientific) supplemented with 10% FBS and 1% Pen/Strep. All cell lines were maintained at 
37◦C and 5% CO2. 
 
Lentiviral production and transduction 
The lentivirus construct pLV411-FOXP3 described previously (Brown et al 2010) encodes 
full length human FOXP3 transcribed from the Elongation factor 1a promoter, whilst 
enhanced green fluorescence protein (eGFP) is expressed from an internal ribosome entry site 
(IRES). Lentivirus preparations were generated as previously described (Barry et al., 2001). 




 flask) cells were transfected with lentiviral transfer 
vector and packaging vectors by reverse transfection using Lipofectamine 2000 transfection 
reagent (Invitrogen, Carlsbad, California USA). A total of 30ug of DNA was used consisting 
of expression vectors for Gag/Pol (7.6ug); Rev (6.4ug); VSV-G (3.6ug) and transfer vector 
containing the gene of interest (12.4ug). The following day medium was replaced and virus 
harvested 72 hours post transfection. Medium was passed through a 0.45um filter to remove 
cellular debris and stored at -80
o
C prior to use. The transfection efficiency of each packaging 
reaction was determined by limiting dilution transduction of HEK 293T cells. Transduced 
cells were identified with flow cytometric detection of GFP-positive cells with viral titres 
determined by calculating the percentage of GFP-positive HEK 293T cells/cell number x 
dilution. Breast cancer cell lines were transduced with lentivirus at a multiplicity of infection 
(MOI) of 2, and sorted for GFP on day 4. Sorted cells were cultured and used for further 
experiments.  
 
Cell proliferation assay 
The proliferative capacity of cells was measured using the CellTiter 96 AQueous One 
Solution Cell Proliferation Assay kit as per the manufacturer’s recommendations (Promega, 
Madison, Wisconsin USA). To measure viability and proliferation of FOXP3-transduced and 
control cell lines cells were plated at 1 x 10
4
 cells in 100ul of the appropriate media in a 96 
well plate in triplicate and the cell proliferation assay performed over a 5 day period. 
Following the addition of CellTiter 96 AQueous One Solution Reagent to triplicate wells the 
plates were incubated at 37
o
C in a humidified 5% CO2 incubator for 1 hour prior to the 
absorbance at 490nm being determined.  
 
Quantitative Real Time PCR 
Total RNA was extracted from all cell lines using the miRNeasy kit (Qiagen, Hilden 
Germany) and subsequently converted to cDNA using the Quantitect Reverse Transcription 
kit (Qiagen). Semi-Quantitative RT-PCR was performed using the KAPA SYBR Fast 
Universal qPCR kit (KAPA Biosystems, Cambridge, Massachusetts USA) in triplicate. PCR 
reactions were performed on a Corbett real time PCR machine (Rotorgene 6000). Results 
from three independent experiments were analysed using Rotor-Gene 6000 software and 
normalised to the expression of reference transcript ribosomal protein L13a (RPL13a). The 





 Target-specific reverse transcription was performed using the Taqman microRNA Reverse 
Transcription kit (Applied Biosystems, Foster City, California USA) and Taqman microRNA 
assay probes for the appropriate miRs (Applied Biosystems, for miR-24, -7, -101 and -155). 
Detection of the mature microRNA forms were performed using specific Taqman microRNA 
assays in the presence of Taqman Universal PCR Mastermix (Applied Biosystems). Assays 
were performed in triplicate on a Corbett Real-time machine (Rotorgene 6000) with miR-24 
used as a reference miR for normalisation. Results from three independent assays were 
analysed using Rotor-Gene 6000 software. 
 
Western Blot and Immunodetection 
Total cell lysate was extracted from cells using RIPA buffer (1% NP-40, 0.1% SDS, 0.1% Na 
Deoxycholate, 100mM NaCl, 2.5mM EDTA, 2.5mM EGTA, 50mM Hepes pH 7.4, 1mM 
Pefablock, 1x complete protease inhibitor cocktail). Protein estimation was performed using a 
Dc assay kit (Bio-Rad, Hercules, California USA).  Western blots were performed with total 
protein (30ug) as per the BD Biosciences protocol for western blotting with monoclonal 
antibodies. Nitrocellulose membranes were probed with a mouse anti-SATB1 monoclonal 
antibody (BD biosciences, Franklin Lakes, New Jersey USA; Clone 14/SATB1). Detection of 
proteins of interest was performed using West Dura Chemiluminescent detection kit (Pierce). 
Band intensities were quantitated using ImageJ 1.43 (http://rsbweb.nih.gov/ij/) after scanning 
on a G: BOX iChemi imager (Syngene, Cambridge UK). As a loading control filters were 
stripped as per instructions for Western Blot Stripping Solution (Alpha Diagnostics, Texas 
USA) and subsequently re-probed with a polyclonal rabbit anti-α-tubulin antibody (Rockland 
Immunochemicals, Gilbertsville, Pennsylvania USA).  
 
Luciferase Constructs and Assays 
Promoter reporter constructs to determine the FOXP3-responsiveness of FOXP3 binding 
regions identified in the human SATB1 gene were constructed as follows; FOXP3 binding 
regions were cloned into the pGL4.24 vector downstream of a minP element and upstream of 
a destabilised firefly luciferase. To measure the response to FOXP3, the SATB1 promoter 
reporter constructs were transfected into parental, FOXP3-expressing or GFP control lines 
together with pGL4.74 renilla luciferase construct using Lipofectamine 2000. Luciferase 
activity was assessed 24 hours after transfection using a Dual Luciferase kit (Promega) as per 
the manufacturer’s instructions in a Veritas luminescent plate reader (Promega).  
 
To determine the effect of specific microRNAs on SATB1 expression and to identify 
functional microRNA binding sites in the 3'UTR of SATB1 (as shown in Figure 1b) the 
3'UTR of SATB1 was amplified by PCR and cloned into the psiCHECK-2 vector (Promega). 
Mutations in putative microRNA binding sites were performed using the KAPA HiFi 
HotStart mutagenesis PCR protocol (Kapa Biosystems, Boston, Massachusetts USA). HEK 
293T cells or breast cancer cell lines were then simultaneously transfected with psiCHECK-2 
constructs and synthetic pre-miR molecules (Ambion) using the miR-optimised Hiperfect 
transfection reagent (Qiagen).  Transfections were performed in triplicate and luciferase 
activity was measured 24 hours later. To determine the effect of pre-miR overexpression on 
endogenous SATB1 levels, breast cancer cell lines (BT549 and MDA-MB-231) were 
transfected with pre-miR molecules using Hiperfect transfection reagent and RNA or protein 





Peptide Nucleic Acid (PNA) microRNA inhibitors for miR-7 and -155 and a control non-
targeting PNA were purchased from Panagene (Daejeon, Korea). To measure knockdown of 
microRNAs in luciferase reporter assays, BT549 cell lines were transfected with reporter 
plasmids and the PNA inhibitors using Lipofectamine 2000 in a 96-well format and luciferase 





Identification of SATB1 as a target for a FOXP3-microRNA feed-forward regulatory loop 
In a previous study we performed ChIP-on-chip experiments to identify genes potentially 
regulated by FOXP3 in human Treg cells (Sadlon et al., 2010). Ingenuity Pathways Analysis 
of these genes indicates a statistically significant enrichment of genes associated with cancer, 
apoptosis, control of growth and proliferation (Supplementary Figure S1). We hypothesised 
that some of these targets may also be regulated by FOXP3 in breast epithelium. 
Furthermore, because a number of microRNAs were found to be regulated by FOXP3 in 
human Treg cells (Sadlon et al., 2010), we searched the list of FOXP3 target genes for genes 
with a known role in cancer, apoptosis and control of growth that were also predicted to be 
targets of microRNAs that are regulated by FOXP3. Putative microRNA binding sites in the 
3'UTRs of candidate FOXP3 target genes were first identified using the microRNA target 
prediction programs in miRGen (http://www.diana.pcbi.upenn.edu/miRGen.html). Then 
using the selection criteria that a candidate binding site must be found in the intersection of 
three separate prediction programs (miRanda, PicTar4 and TargetScan), we identified SATB1 
as a gene that has multiple binding sites for FOXP3 in its promoter region (Figure 1a) as well 
as predicted binding sites for the FOXP3-regulated miR-7 and miR-155 in its 3' UTR (Figure 
1b).      
 
FOXP3 over expression reduces SATB1 levels in BT549  
In order to determine if FOXP3 levels influence SATB1 expression in breast cancer cells the 
lentiviral pLVEIG-FOXP3 vector was used to stably express human FOXP3 in BT549 human 
breast cancer cells. BT549 cells have been demonstrated previously to express SATB1 which 
is associated with their metastatic potential (Han et al., 2008) and express low/negligible 
levels of FOXP3 (Figure 2). Multiple independent transductions of BT549 cells with either a 
FOXP3-containing lentivirus or a control GFP-marked vector yielded cell lines in which long 
term stable expression of the vector was observed (Supplementary Figure S2). A reduction in 
proliferative capacity of the BT549 cell line was observed when FOXP3 was stably over 
expressed (Supplementary Figure S3), and comparison of the GFP-transduced cells with the 
parental cell lines confirmed this reduction was not due to the effects of lentiviral integration. 
FOXP3 over expression in BT549 cells was not associated with significant loss of viability.  
 
The impact of FOXP3 expression on SATB1 levels in BT549 cells was then determined by 
RT-PCR and western blot analysis. SATB1 mRNA levels were reduced by ~60% (p<0.0001, 
n=3 separate transduction pools) in BT549 cell lines in which FOXP3 was over expressed 
compared to un-transduced BT549 cells (Figure 2a). In contrast, SATB1 mRNA levels were 
not significantly altered when cells were transduced with a GFP-expressing control vector. 
The effect of FOXP3 on SATB1 protein levels was confirmed by western blot (Figure 2b). 
Together these data indicate that FOXP3 is capable of repressing SATB1 levels in breast 
cancer cell lines.  
 
 FOXP3 regulates SATB1 transcription in BT549  
FOXP3 Chromatin immunoprecipitation arrays (ChIP-on-chip) in Treg cells indicated several 
potential binding interactions in the SATB1 locus (Figure 1a), suggesting that the SATB1 
promoter may be responsive to FOXP3. To test whether FOXP3 directly represses the SATB1 
promoter in breast cancer cells, we constructed SATB1-promoter luciferase reporter 
constructs. These were transfected into either control BT549 cells or BT549 cells expressing 
FOXP3. We examined the FOXP3-dependent regulation of two binding regions (BR-1 and 
BR-2) located -3kb and +0.5kb upstream and downstream from the SATB1 transcription start 
site (TSS) respectively. BT549 cells transfected with a SATB1 promoter reporter containing 
either FOXP3 BR-1 or BR-2 showed significant repression in BT549-FOXP3 cells compared 
to BT549 or BT549-GFP cells (Fig. 3)(BR-1 ~75% repression, p<0.0001and BR-2 ~40% 
repression p=0.048 respectively for n=3 independent experiments). Importantly, when the 
FOXP3 binding consensus sequences located in BR-1 or BR-2 were mutated the FOXP3-
dependent repression of luciferase activity was abolished. In addition, no effect of FOXP3 
expression was observed on a control promoter construct (psiCHECK control) in which 
luciferase transcription was driven by the HSV-TK promoter. Together these data indicate 
that FOXP3 is able to directly regulate the SATB1 promoter in BT549 cells.  
  
FOXP3-induced microRNA expression in BT549 
 We hypothesised that FOXP3 may act additionally via microRNAs to down-regulate SATB1 
in breast epithelial cells. In particular we focussed on miR-155 and miR-7 as these 
microRNAs have predicted binding sites located within the 3'UTR of SATB1. FOXP3 binding 
regions in close proximity to the loci encoding miR-155 and two of the three genomic loci 
encoding miR-7 (miR-7-1 and miR-7-2) have been previously identified (Sadlon et al., 
2010). To determine if FOXP3 can alter the expression level of these microRNAs, the 
relative levels of miR-7 and miR-155 in BT549 cells expressing pLVEIG FOXP3 were 
compared to parental BT549 cells as determined by qRT-PCR.  Relative to the parental 
BT549 cell line or cells transduced with the GFP control lentivirus, there were significantly 
elevated levels of miR-7 and miR-155 in the BT549-FOXP3 cells, suggesting that FOXP3 




Downregulation of SATB1 by microRNAs -7 and -155 
To determine whether miR-7 and miR-155 directly target SATB1 in breast cancer cells, we 
constructed a luciferase reporter containing the SATB1 3'UTR. The reporter gene was co-
transfected into BT549 cells along with pre-miRs for miR-7, miR-155, a combination of both, 
or a non-targeting random sequence control pre-miR. When tested over a range of 
concentrations, a significant dose-dependent reduction in the levels of SATB1 3'UTR reporter 
activity was observed for miR-7 alone (60% reduction, p=0.03), miR-155 alone (55% 
reduction, p=0.03), and the combination of the two miRs (70% reduction, p<0.0001), but not 
the non-targeting control miR (Figure 5a). No miR-dependent reduction in the renilla activity 
of a control reporter construct lacking the SATB1 3'UTR sequences was observed (Figure. 
5b). Sequence mutations were then introduced to disrupt the miR seed sequences for miR-7 
and miR-155 either alone or in combination in the SATB1 3'UTR reporter constructs (Figure 
1b). These constructs were co-transfected into BT549 cells with a control miR, pre-miR-7 or 
pre-miR-155. Mutation of either of the putative miR binding sites within the SATB1 3'UTR 
abolished the ability of the corresponding pre-miR to down-regulate renilla luciferase activity 
whilst mutation of both miR seed sites prevented the down-regulation of renilla activity by 
either miR (Figure 5b). We observed similar miR-7 and miR-155 down-regulation of SATB1 
3'UTR reporter construct activity in MDA-MB-231 cells, a second breast cancer cell line 
known to express high levels of SATB1 protein (Han et al 2008) (Supplementary Figure S4).  
These observations suggest that the SATB1 3'UTR contains functional binding sites for miR-7 
and miR-155 and together the level of these two miRs contribute to the overall level of 




Endogenous miR-7 and miR-155 regulate SATB1 levels in BT549 cells  
To verify that the endogenous miR-7 and miR-155 in BT549 cells can regulate SATB1, we 
used peptide nucleic acid (PNA) inhibitor molecules against miR-7 or miR-155 to block miR-
7 and miR-155 activity respectively. BT549 cells expressing either FOXP3 or GFP alone 
were transiently co-transfected with psiCHECK/SATB1 3'UTR reporter constructs and either 
a control PNA miR inhibitor or specific miR-7 and miR-155 PNA inhibitors. In cells 
expressing GFP alone, co-transfection with PNA inhibitors (100-200nM) to either miR-7 or 
miR-155 resulted in a 30-40% increase in reporter activity =3 p<0.0001) whereas no 
significant effect on renilla luciferase activity was observed with the control PNA inhibitor at 
these concentrations (Figure 6). In BT549 cells expressing FOXP3, a 45% reduction in the 
SATB1 3'UTR reporter activity relative to BT549 cells expressing GFP alone was apparent in 
the absence of PNA inhibitors (n=3 p<0.0001), consistent with the FOXP3-dependent 
increase in the expression of these miRs observed in these cells (Figure 4). Co-transfection of 
these cells with 200nM miR-7 or miR-155 PNA inhibitors caused a 30-40% (p=0.004) dose-
dependent PNA-specific reversal of the inhibition of the SATB1 3'UTR reporter constructs 
compared with the BT549 GFP no miR inhibitor control. When compared with the BT549 
FOXP3 no miR-i control this represents a 50-60% increase in SATB1 reporter activity. No 
significant effects on the reporter activity were observed when FOXP3-expressing cells were 
co-transfected with control PNA inhibitors. Similar increases in reporter activity were 
observed when parental BT549 cells were treated with miR-7 and miR-155 inhibitor, but not 
control PNA inhibitor (Supplementary Figure S5).  
 
Repression of endogenous SATB1 by microRNAs -7 and -155 
To determine if miR-7 and miR-155 could repress endogenous SATB1, the parental BT549 
cell line, GFP-transduced BT549 cells and FOXP3-overexpressing BT549 cells were 
transfected either with a control pre-miR, pre-miR-7 or pre-miR-155.  Transfection of the 
parental and GFP cell lines with either pre-miR-7 or pre-miR-155 caused a significant 
reduction in SATB1 mRNA levels compared to control pre-miR transduced cells (35-38% 
p=6.35x10
-5
 and 35-45% p=1.4x10
-9
 reduction respectively) (Figure 7a). In FOXP3-
transduced cells transfected with the control pre-miR, endogenous SATB1 mRNA levels were 
decreased 45-50% (p= 1.03x10
-12
) compared to control pre-miR transfected parental or GFP 
transduced cell lines. This was considered to be most likely due to the combination of 
FOXP3-dependent repression of SATB1 transcription and up-regulation of endogenous miR-7 
and miR-155 levels within these cells. Importantly, when pre-miR-7 or pre-miR-155 were 
transfected into FOXP3-expressing cells a further significant decrease in SATB1 mRNA 
levels was observed with a 40-43% (=3.12x10
-5
) and 70-72% (p=1.35x10
-8
) reduction in 
SATB1 mRNA observed in miR-7 and miR-155 transfected cells respectively. When 
compared to the control SATB1 expression levels in BT549 cells, the additive effects of 
FOXP3 and miR-7 or miR-155 account for a 70-80% reduction in SATB1 expression. These 
findings were confirmed at the protein level by western blot assay of SATB1 protein 
expression (Figure 7b). To quantitate the effect of FOXP3 and miR-7 and miR-155 on 
SATB1 protein levels, three independent western blots were analysed and the relative level of 
SATB1 was normalised to alpha tubulin (Figure 7c). A significant miR-7 and miR-155-
dependent reduction in SATB1 protein levels was observed in all three cell lines. 
Additionally, FOXP3 expression alone caused a reduction in SATB1 protein levels, with 
further reduction in SATB1 levels detected when these cells were also transfected with pre-
miR-7 or pre-miR-155. Together these findings suggest that FOXP3 acts to negatively 
regulate SATB1 levels both directly, through the repression of SATB1 transcription, and 
indirectly through the induction of miR-7 and miR-155 that then target the 3'UTR of SATB1 
mRNA.         
Discussion 
 
Recently the transcription factor FOXP3, a master regulator of Treg cells, has been proposed 
to function as a tumour suppressor within breast and prostate epithelial cells (Wang et al., 
2009; Zuo et al., 2007b), although the molecular pathways and targets it regulates are yet to 
be explored in detail. In Treg cells FOXP3 orchestrates its transcriptional program both by 
directly binding to gene regulatory regions and also indirectly by controlling other regulators 
such as transcription factors and microRNAs (Gavin et al., 2007; Hill et al., 2007; Sadlon et 
al., 2010; Williams and Rudensky, 2007; Zheng et al., 2007). In this work we demonstrate 
that FOXP3 can also carry out its tumour suppressor function in epithelial cells by direct and 
indirect mechanisms. Specifically, we show that in breast cancer cell lines SATB1 is 
repressed by FOXP3 both directly, by FOXP3 binding to regulatory regions within the 
SATB1 gene, and indirectly through FOXP3-induction of two miRs; miR-7 and miR-155, 
which themselves target the 3'UTR of SATB1. This suggests that part of FOXP3 tumour 
suppressor activity within normal breast may be via the suppression of SATB1 expression. 
SATB1 has recently been proposed to be an important mediator of epithelial-mesenchymal 
transitions (EMT) and metastasis in breast cancer. Furthermore, SATB1 protein expression 
has been linked to poor prognosis in a large cohort of breast cancer patients (Han et al., 2008; 
Hanker et al., 2010; Kohwi-Shigematsu et al., 2010). Although there are contradictory 
reports on the prognostic value of SATB1 expression in breast cancer based upon the 
assessment of transcript levels (Hanker et al., 2010; Iorns et al., 2010), contamination of 
SATB1 signals from other cell types such as activated stromal cells or infiltrating T 
lymphocytes may explain this (Kohwi-Shigematsu et al., 2010).  Critically, Han et al scored 
SATB1 protein expression only in tumour cells (Han et al., 2008), which gave a strong 
prognostic correlation. Three recent studies indicated that high SATB1 mRNA levels 
correlated with advanced stages of cancer and poor prognosis in breast (Patani et al., 2009) 
and gastric cancer (Cheng et al., 2010; Lu et al., 2010).  SATB1 expression has also recently 
been linked to the acquisition of multidrug resistance in MCF7 cells (Li et al., 2010b) and in 
chemotherapy induced-EMT within breast cancer (Li et al., 2010a). Together these findings 
are consistent with SATB1 playing an important role in cancer.  
Little is known about the regulation of SATB1 levels and, in particular, the mechanism by 
which SATB1 expression is induced in breast cancer. We show for the first time that FOXP3 
and FOXP3-induced miRs are able to form a feed-forward loop to control SATB1 expression 
in breast cancer cells. Potentially, the up-regulation of FOXP3 or FOXP3-regulated miRs 
may provide a new therapeutic opportunity for the treatment of breast cancer. As a 
consequence of FOXP3 being subject to random X-inactivation, only a single allele of 
FOXP3 needs to be mutated to inactivate FOXP3 function (Liu et al., 2010). Indeed thus far 
the majority of mutations and deletions of FOXP3 found in breast cancer samples are 
heterozygous, with only the FOXP3 allele on the active X-chromosome mutated (Zuo et al., 
2007a; Zuo et al., 2007b). This raises the possibility of re-activating the wild type allele as a 
potential cancer therapy as recently demonstrated in normal and malignant mammary cells in 
vitro (Liu et al., 2009b). 
Our findings establish a link between FOXP3 expression and the suppression of metastatic 
potential, at least in part through the regulation of SATB1. Other mechanisms also participate 
in the suppression of SATB1 within breast epithelial cells, including induction of other miRs 
such as miR-488 (Li et al., 2010a). FOXP3 loss appears to occur more frequently in primary 
breast cancer cells and breast cancer cell lines than does SATB1 induction (Han et al., 2008; 
Zuo et al., 2007b), suggesting that FOXP3 may also regulate other genes involved in cancer. 
Together, these findings indicate that SATB1 expression is tightly regulated within breast 
epithelia both through transcriptional control and post-transcriptionally through microRNAs.   
The finding that FOXP3 can regulate miR-7 and miR-155 in breast cancer cell lines suggests 
that aberrant expression of miRs may be an important consequence of loss of FOXP3 activity 
in primary tumour cells.  The aberrant expression of other miRs in cancer cells has also been 
recently linked to the loss and/or oncogenic activation of transcription factors with tumour 
suppressor function or oncogenic potential respectively (Bommer et al., 2007; O'Donnell et 
al., 2005; Reddy et al., 2008; Sander et al., 2008). The exact role for the FOXP3-induced 
miRs identified in our study in normal and cancerous epithelial cells is yet to be determined, 
as each miR can potentially target multiple transcripts (Farazi et al., 2010).  However, 
experimentally validated miR-7 targets including growth factor receptors and signalling 
molecules including EGFR, PAK1, RAF-1, IRS1 and IRS2 are frequently up-regulated in 
cancers (Kefas et al., 2008; Pogribny et al., 2010; Reddy et al., 2008), supporting a role for 
miR-7 in FOXP3 tumour suppressor function. We have also observed reduced mRNA levels 
for the miR-7 targets EGFR, PAK1 and RAF-1 in FOXP3 transduced BT549 cells correlating 
with the increased miR-7 levels (Supplementary Figure S6), suggesting that in addition to 
suppressing SATB1, miR-7 may also suppress other important oncogenes within these cells. 
Although increased miR-7 levels  have been associated with aggressiveness in estrogen 
receptor-positive (ER+) breast cancers (Foekens et al., 2008), the recent finding that miR 
inhibitory effects are generally less potent in ER+ breast cancers provides a possible 
explanation for this apparent contradiction (Cheng et al., 2009). Clearly, further work is 
required to determine the role miR-7 has in breast cancer pathogenesis. Similarly, the role of 
miR-155 needs further clarification. MiR-155 is over-expressed in many cancers including 
breast cancer where it has been shown to promote growth and cell survival (Blenkiron et al., 
2007; Iorio et al., 2005; Kong et al., 2010), which is apparently at odds with its ability to 
target the SATB1 oncogene as identified in this study, and inconsistent with it playing a role 
in FOXP3 tumour suppressor function.  These seemingly contradictory findings may reflect 
the difference between the function of a specific miR in the context of a cancerous cell 
compared to a normal cell.  Presumably within a normal epithelial cell, as observed for Treg 
cells (Kohlhaas et al., 2009; Lu et al., 2009), FOXP3 contributes to a steady state level of 
miR-155 required for normal cellular and/or tissue homeostasis. However within the context 
of multiple changes that occur within a cancerous cell, increased levels of miR-155 may have 
a deleterious effect.  
We propose that re-expression of FOXP3 in cancer cells, in which FOXP3 expression has 
been lost, will result in FOXP3-mediated up-regulation of miR-155, miR-7 and other miRs, 
restoring the regulation which normally occurs in non-malignant cells. In summary, we have 
identified a feed-forward loop involving FOXP3 and FOXP3-induced microRNAs and 
demonstrated that the oncogene SATB1 is a target for suppression by this loop (Figure 8). The 
identification of other potential targets of FOXP3-dependent feed-forward regulatory loops 
may provide additional candidates for intervention in breast cancer. 
  















 Figure 2 Endogenous SATB1 is reduced when FOXP3 is over expressed in BT549  
 
 





























































a) The gene structure of the human SATB1 locus showing its 11 exons, and the human 
FOXP3 binding regions defined by chromatin immunoprecipitation in human regulatory T 
cells, revealing 5 potential FOXP3 binding regions (BR1-5). The SATB1 proximal promoter 
is shown close to BR1 and BR2. b) Annotation of the SATB1 3'UTR showing predicted miR-
155 and miR-7 seed sequences and subsequent introduced mutations. 
 
Figure 2 
SATB1 is repressed in BT549 cells over expressing FOXP3. a) SATB1 mRNA levels in the 
parental BT549 cells (dark grey), BT549 over expressing GFP (light grey) and BT549 over 
expressing FOXP3 (hatched) (n=3). b) SATB1 protein expression (upper row) as determined 
by western blot is detected in the parental BT549 cells, but is reduced in cells expressing 
FOXP3 (middle row). The loading control is α-tubulin (bottom row), *= p<0.05. 
  
Figure 3 
Luciferase reporter assay in BT549 cells using promoter constructs containing either WT 
FOXP3 binding sites at BR-1 and BR-2 or mutations of each site. When FOXP3 is over 
expressed in these cells (hatched bars) the WT reporter is repressed, and repression is lost by 
mutation of either binding site. Data are expressed relative to the parental line (dark grey 




RT-PCR quantitation of miRs -7, -155 and -19b in three independent lentivirally transduced 
FOXP3-overexpressing pools of BT549 cells. Significant upregulation of miRs -7 and -155 is 
observed when FOXP3 is expressed relative to levels in the control GFP-transduced cell line, 
with no change in miR-19b levels observed. 
 
Figure 5 
a)   Transient expression of pre-miRs -7 and -155 in BT549 cells expressing a luciferase 
reporter construct containing the SATB1 3'UTR (grey bars) or empty reporter vector (white 
bars), showing that either alone or in combination, these miRs repress the SATB1 reporter in a 
dose dependant manner over the range 5-20nM. Results are normalised to the control pre-
miR (n=3). b) Mutations of the miR-7 or miR-155 sites in the 3'UTR of the reporter vector 
were tested alone or in combination. Cells were transfected with control pre-miR (white 
bars), by pre-miR-7 (black bars) or pre-miR-155 (dotted bars) (n=3, *= p<0.05). 
 
Figure 6 
 Transient expression of PNA inhibitor (PNAi) targeting miR-7 or miR-155 specifically 
inhibits the miR-mediated repression of the SATB1 3'UTR reporter construct in a dose 
dependant manner.  BT549 cells expressing GFP (grey bars) or BT549 cells over expressing 
FOXP3 (hatched bars) show a PNAi-induced increase in SATB1 3'UTR expression, (n=3, *= 
p<0.001 compared with the BT549 GFP no miR-i control, **=p<0.001 compared to the 
BT546 FOXP3 no miR-i control, ***=p<0.05 compared to the BT549 GFP no miR-i 
control). 
Figure 7 
 a) Expression of the endogenous SATB1 mRNA is reduced when pre-miRs -7 or -155 are 
transiently expressed in BT549 cells. SATB1 levels in the parental BT549 cells (dark grey 
bars) are reduced by the transfection of miR-7 or miR-155, as is seen in the GFP-transduced 
line (grey bars). Over expression of FOXP3 alone (hatched bars) reduces SATB1 levels, as 
shown by the control miR, and further reduces SATB1 when the pre-miRs are transiently 
expressed in these cells. (Triplicate RNA analysis of n=3 transfection pools). b)  A 
representative SATB1 western blot of whole cell lysates from one of three independent 
transfection pools. c) Quantitation of SATB1 protein levels by scanning densitometry of 
immunoblots, normalised to the tubulin loading control, n=3. 
 
Figure 8 
A schematic representation of the feed-forward regulation of SATB1 by FOXP3.  FOXP3 acts 
both directly at the 5' promoter region and indirectly by inducing miRs that target the 3'UTR. 
FOXP3 may induce other tumour suppressors and repress other oncogenes to give tight 
regulation of the protein. 
  
Supplementary Figures 
Figure S1 The top disease associations of human FOXP3 ChIP targets identified with 
Ingenuity Pathway Analysis (IPA). Axis is Benjamini-Hochberg adjusted p-value. 
 
 
Figure S2 Stable expression of FOXP3 in BT549 breast cancer cells. 
The percentage of cells positive for GFP, expressed from an internal ribosome entry site in 
PLVEIG,  was tracked for up to 8 passages post-sorting in FOXP3 and control vector 
transduced cell lines by flow cytometry (n=3). Approximately 80% of BT549 cells 




Figure S3 The proliferation of BT549 cells expressing FOXP3 is impaired. 
 The proliferation of BT549 cells expressing FOXP3 was compared to parental and control 
GFP expressing cells using the CellTiter 96 AQueous assay (Promega). Bars represent the 
SEM of triplicate samples. The figure is a representative of three experiments using cells 











Figure S4. The SATB1 3'UTR is directly targeted by miR-7 and miR -155 in the MDA-MB-
231 line 
Transient expression of pre-miRs -7 and -155 in MDA-MB-231 cells expressing a luciferase 
reporter construct containing the SATB1 3'UTR (grey bars) or empty reporter vector (white 
bars), showing that either alone or in combination, these miRs repress the SATB1 reporter  in 
a dose dependant manner over the range 5-20nM. Results are normalised to the control pre-
miR (n=3).  
 
 Figure S5. miR targeting of SATB1 is blocked in parental BT549 by PNA oligos. 
Transient expression of PNA inhibitor (PNAi) targeting miR-7 or miR-155 specifically 
inhibits the miR-mediated repression of the SATB1 3'UTR reporter construct in a dose 
dependant manner.  BT549 cells (white bars) show a PNAi-induced increase in SATB1 












Figure S6. Validated miR-7 target are decreased in FOXP3 transduced cells. 
The mRNA levels of the validated miR-7 targets, EGFR, RAF-1 and PAK-1, were determined 
by qPCR in parental BT549 cells (dark grey), control GFP expressing (light grey) and 
FOXP3 expressing (hatched) BT549 cells. A significant reduction in the mRNA level of 
these targets was observed in FOXP3 expressing cells but not control GFP expressing cells. 
Shown is the data from three independent experiments. 
 
 Table S1 List of PCR primers used in this study 
  
 Forward (5’-3’)  Reverse (5’-3’)  
SATB1  ACA GGT GCA AAA ATG CAG GGA  GCG TTT TCA TAA TGT TCC ACC AC  
RPL13a  CGA GGT TGG CTG GAA GTA CC  CTT CTC GGC CTG TTT CCG TAG  
FOXP3  GTC TGG GCT CAT AGG CAC ATT  ATG GCG TTC TGT GGA AGG C  
SATB1 3’UTR  CAG CCA GCT GTA ACA AAA TAG C  GAA GAA GAG CTG TCA GTG GAA G  
miR-7 mutant  TGT TTG CAA TGT GGA ACC CTT TGG TTT ACA  TGT AAA CCA AAG GGT TCC ACA TTG CAA ACA  
miR-155 mutant  GAG CCT CAA ACA ATC GAA ATA CCT TCT GTG  CAC AGA AGG TAT TTC GAT TGT TTG AGG CTC  
RAF-1 GCA CTG TAG CAC CAA AGT ACC  CTG GGA CTC CAC TAT CAC CAA TA  
PAK-1 TAC CAG CAC TAT GAT TGG AGT CG  GGA TCG GTA AAA TCG GTC CTT CT  
EGFR GCG TTC GGC ACG GTG TAT AA  GGC TTT CGG AGA TGT TGC TTC  
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